These results highlight semaglutides early action on decreasing major cardiovascular events, with significant benefits already evident by the first 6 months, and for some, even earlier, even before any major weight loss and before most patients would have been titrated to their full target dose of 2.4 mg, said lead author Dr Jorge Plutzky, Director of Preventive Cardiology, Cardiovascular Medicine at Brigham and Womens Hospital, Boston, MA, USA and a member of SELECT Steering Committee
The NAION docket runs parallel to the existing federal GLP-1 MDL addressing other alleged injuries, including gastrointestinal harms, and is assigned to the same judge in the U.S
While defendants argue for strict diagnostic requirements, plaintiffs maintain that clinical presentation sufficiently establishes injury when patients improved after discontinuation
some FAQs at the bottom of pages list a starter monthly rate for a single product
This is the turning point